Dona Ferentes
Pengurus pengatur
- Joined
- 11 January 2016
- Posts
- 16,304
- Reactions
- 22,247
quarterly out, 3 days of drops from $0.80 and now as low as $0.58
FINANCIAL HIGHLIGHTS
• Positive cash flows from operations of NZ$1.2 million during the quarter, reflecting the first quarter of positive cash flow since admission to the ASX in July 2020.
• Total cash on hand increased by NZ$0.3 million, ending the quarter with a strong cash balance of NZ$21.9 million.
• Strong cash receipts from customers of NZ$19.5 million during the quarter, in line with expectations.
• Net cash outflow from investing activities was NZ$0.8 million for the quarter, primarily reflecting routine capital expenditure.
• Full-year FY25 guidance (on a reported basis), is expected to be NZ$81-84 million total revenue (a 17-22% increase on FY24) and a normalised EBITDA profit of NZ$2-4 million.
OPERATIONAL HIGHLIGHTS
• The first peer reviewed study to emerge from the Company’s larger ‘MASTRR’ study was published in December. The real-world limb salvage study found Myriad Matrix™ and Myriad Morcells™ achieved tissue fill and coverage within 30 days with just one application and no complications. The findings of the study reinforce the efficacy of Myriad™ products in complex limb salvage procedures.
• AROA direct sales are now contributing 56% of the year-to-date sales mix, with Myriad expected to continue growing, becoming a larger part of the overall sales mix
• Regulatory approval received for Endoform™ and Myriad Matrix in Lebanon, Endoform in Vietnam, and Myriad in Saudi Arabia.
FINANCIAL HIGHLIGHTS
• Positive cash flows from operations of NZ$1.2 million during the quarter, reflecting the first quarter of positive cash flow since admission to the ASX in July 2020.
• Total cash on hand increased by NZ$0.3 million, ending the quarter with a strong cash balance of NZ$21.9 million.
• Strong cash receipts from customers of NZ$19.5 million during the quarter, in line with expectations.
• Net cash outflow from investing activities was NZ$0.8 million for the quarter, primarily reflecting routine capital expenditure.
• Full-year FY25 guidance (on a reported basis), is expected to be NZ$81-84 million total revenue (a 17-22% increase on FY24) and a normalised EBITDA profit of NZ$2-4 million.
OPERATIONAL HIGHLIGHTS
• The first peer reviewed study to emerge from the Company’s larger ‘MASTRR’ study was published in December. The real-world limb salvage study found Myriad Matrix™ and Myriad Morcells™ achieved tissue fill and coverage within 30 days with just one application and no complications. The findings of the study reinforce the efficacy of Myriad™ products in complex limb salvage procedures.
• AROA direct sales are now contributing 56% of the year-to-date sales mix, with Myriad expected to continue growing, becoming a larger part of the overall sales mix
• Regulatory approval received for Endoform™ and Myriad Matrix in Lebanon, Endoform in Vietnam, and Myriad in Saudi Arabia.
